Remedent, Inc. Expects Revenues to Increase over $1 Million to Approximately $2.5 Million in Second Quarter Fiscal 2006
October 04 2006 - 6:00AM
Business Wire
Remedent, Inc. (OTC BB: REMI) a leader in the research and
development, manufacturing and marketing of oral care and cosmetic
dentistry products, announced that it expects revenues for the
second quarter 2006 to be approximately $2.5 million. This
represents an increase of more than $1 million over the second
quarter fiscal 2005 result. The Company further anticipates
overheads and margins to stay in line with the previous year. Guy
De Vreese, Chairman of Remedent, stated, �We are very pleased that
we have achieved significant market penetration in various European
and Asian markets, and our selective efforts to grow our footprint
in America are on track.� He added, �The iWhite over-the-counter
business has grown with the signing of new distribution contracts
recently. These include deals with Pierre Fabre, Chefaro Italy and
Chefaro Spain, and Douglas Germany. We estimate that total
retailers served by these distributors will be roughly 19,000 and
we have a goal of being in at least 48,000 retail outlets. This
business is also expanding in China, with the signing of a
distribution agreement with Sephora China, and we are signing a
distribution agreement with Drugstore.com to help increase its
cyberspace presence.� De Vreese further said, �We continue to
develop our professional treatment business. We have finished
revamping the new MetaTray in-office treatment. We see a shift of
the business towards the cosmetic market, and our revamping
addressed that need. In many markets, including the US, we are
actively supporting this through a number of OEM relationships. In
the US, we are dealing with IMDS, a California-based dealer that
has started to target the cosmetic market. In Europe, we are
dealing with Universal Bright, an organization that reaches out to
the professional cosmetic treatment market.� De Vreese also said,
�We are expanding our range of products with a kit to treat
sensitive teeth. The new product is called �RemeSense,� and it will
be offered to our existing retail channel. It is based on the same
technology currently used in our iWhite range of products.
RemeSense has a huge market potential because roughly a quarter of
the total population suffers from some form of tooth sensitivity.
Moreover, we have conducted a very successful patient test that
demonstrates the efficacy of the treatment.� De Vreese concluded,
�After three years of research and development, we are launching
the Glamsmile veneer business, a revolutionary instant smile
service. We are supporting the opening of two retail outlets, which
will focus on veneer and whitening. The first openings are in
Beijing, China and Rotterdam, Holland. In addition to the stores,
the service will be made available to affiliated, trained dentists
in addition to the MetaTray treatment we currently offer them.�
Management of Remedent will host a conference call today at 10:00
A.M. EDT. The call will include comments about the progress of its
business and provide guidance for the next 12-15 months. Those who
wish to participate in the call may telephone 888-335-6674, (US),
or 973-935-2981, (international callers), passcode #7935948
approximately 15 minutes before the 10:00 A.M. EST starting time.
If you cannot participate in the call but wish to listen to it, you
may login at Remedent�s website at www.remedent.com. You will be
able to listen by either Windows Media or Real Player approximately
2 hours after the completion of the call. About Remedent Remedent,
Inc. strives to be a world leader in the research and development,
manufacturing and marketing of oral care and cosmetic dentistry
products. Remedent products are renowned for their technological
superiority and ease-of-use. Based in Deurle, Belgium and El
Segundo, CA, Remedent has successfully researched, developed and
manufactured all of its own products. These products are now
distributed in more than 35 countries worldwide. Remedent consists
of two divisions: one that serves the dental community and one that
is focused on the over-the-counter consumer market. Visit
www.remedent.com for further information. Certain matters discussed
in this press release are �forward-looking statements� intended to
qualify for the safe harbors from liability established by the
Private Securities Litigation Reform Act of 1995. In particular,
the Company�s statements regarding trends in the marketplace and
potential future results are examples of such forward-looking
statements. The forward-looking statements include risks and
uncertainties, including, but not limited to, the consummation and
the successful integration of proposed acquisitions, the timing of
projects due to the variability in size, scope and duration of
projects, estimates made by management with respect to the
Company�s financial results, backlog, critical accounting policies,
regulatory delays, clinical study results which lead to reductions
or cancellations of projects, and other factors, including general
economic conditions and regulatory developments, not within the
Company�s control. The factors discussed herein and expressed from
time to time in the Company�s filings with the Securities and
Exchange Commission could cause actual results and developments to
be materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance. Remedent, Inc. (OTC BB: REMI) a
leader in the research and development, manufacturing and marketing
of oral care and cosmetic dentistry products, announced that it
expects revenues for the second quarter 2006 to be approximately
$2.5 million. This represents an increase of more than $1 million
over the second quarter fiscal 2005 result. The Company further
anticipates overheads and margins to stay in line with the previous
year. Guy De Vreese, Chairman of Remedent, stated, "We are very
pleased that we have achieved significant market penetration in
various European and Asian markets, and our selective efforts to
grow our footprint in America are on track." He added, "The iWhite
over-the-counter business has grown with the signing of new
distribution contracts recently. These include deals with Pierre
Fabre, Chefaro Italy and Chefaro Spain, and Douglas Germany. We
estimate that total retailers served by these distributors will be
roughly 19,000 and we have a goal of being in at least 48,000
retail outlets. This business is also expanding in China, with the
signing of a distribution agreement with Sephora China, and we are
signing a distribution agreement with Drugstore.com to help
increase its cyberspace presence." De Vreese further said, "We
continue to develop our professional treatment business. We have
finished revamping the new MetaTray in-office treatment. We see a
shift of the business towards the cosmetic market, and our
revamping addressed that need. In many markets, including the US,
we are actively supporting this through a number of OEM
relationships. In the US, we are dealing with IMDS, a
California-based dealer that has started to target the cosmetic
market. In Europe, we are dealing with Universal Bright, an
organization that reaches out to the professional cosmetic
treatment market." De Vreese also said, "We are expanding our range
of products with a kit to treat sensitive teeth. The new product is
called 'RemeSense,' and it will be offered to our existing retail
channel. It is based on the same technology currently used in our
iWhite range of products. RemeSense has a huge market potential
because roughly a quarter of the total population suffers from some
form of tooth sensitivity. Moreover, we have conducted a very
successful patient test that demonstrates the efficacy of the
treatment." De Vreese concluded, "After three years of research and
development, we are launching the Glamsmile veneer business, a
revolutionary instant smile service. We are supporting the opening
of two retail outlets, which will focus on veneer and whitening.
The first openings are in Beijing, China and Rotterdam, Holland. In
addition to the stores, the service will be made available to
affiliated, trained dentists in addition to the MetaTray treatment
we currently offer them." Management of Remedent will host a
conference call today at 10:00 A.M. EDT. The call will include
comments about the progress of its business and provide guidance
for the next 12-15 months. Those who wish to participate in the
call may telephone 888-335-6674, (US), or 973-935-2981,
(international callers), passcode #7935948 approximately 15 minutes
before the 10:00 A.M. EST starting time. If you cannot participate
in the call but wish to listen to it, you may login at Remedent's
website at www.remedent.com. You will be able to listen by either
Windows Media or Real Player approximately 2 hours after the
completion of the call. About Remedent Remedent, Inc. strives to be
a world leader in the research and development, manufacturing and
marketing of oral care and cosmetic dentistry products. Remedent
products are renowned for their technological superiority and
ease-of-use. Based in Deurle, Belgium and El Segundo, CA, Remedent
has successfully researched, developed and manufactured all of its
own products. These products are now distributed in more than 35
countries worldwide. Remedent consists of two divisions: one that
serves the dental community and one that is focused on the
over-the-counter consumer market. Visit www.remedent.com for
further information. Certain matters discussed in this press
release are "forward-looking statements" intended to qualify for
the safe harbors from liability established by the Private
Securities Litigation Reform Act of 1995. In particular, the
Company's statements regarding trends in the marketplace and
potential future results are examples of such forward-looking
statements. The forward-looking statements include risks and
uncertainties, including, but not limited to, the consummation and
the successful integration of proposed acquisitions, the timing of
projects due to the variability in size, scope and duration of
projects, estimates made by management with respect to the
Company's financial results, backlog, critical accounting policies,
regulatory delays, clinical study results which lead to reductions
or cancellations of projects, and other factors, including general
economic conditions and regulatory developments, not within the
Company's control. The factors discussed herein and expressed from
time to time in the Company's filings with the Securities and
Exchange Commission could cause actual results and developments to
be materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Elysee Development (PK) (USOTC:ASXSF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Elysee Development (PK) (USOTC:ASXSF)
Historical Stock Chart
From Oct 2023 to Oct 2024